Abstract
Obesity has emerged as a pervasive and multifaceted global health dilemma, with the attendant condition of insulin resistance frequently preceding and accelerating the onset of type 2 diabetes and related metabolic perturbations. A growing body of literature has correlated the dietary augmentation of omega-3 fatty acids with ameliorations in insulin action. Yet, the precise intracellular and intercellular pathways through which these fatty acids exert their effects remain inadequately delineated. Chronically, the frail genomic networks that are, the compendium of regulatory and genomic elements governing lipid metabolism and insulin signaling, are now amenable to in-depth analysis, permitting the high-resolution interrogation of perturbations imposed by omega-3 fatty acids supplementation. This investigative program, therefore, leverages a nutrigenomic framework to systematically catalogue transcriptional, post-transcriptional, and epigenetic modifications elicited by omega-3 fatty acids ingestion in a representative cohort of clinically defined obesity and insulinresistant adults, to delineate the regulatory circuitry that links omega-3 supplementation to the recovery of normal insulin receptor and post-receptor signaling. Leveraging omega-3 fatty acids dietary supplementation in conjunction with sophisticated nutrigenomic profiling, the present investigation quantifies alterations in biomarkers of insulin sensitivity while elucidating hereditary determinants that modulate therapeutic variance in response to omega-3 fatty acids intake. Such a biophysiological and genomic convergence aims to inform precision-structured dietary regimens targeting obesity and its attendant metabolic pathophysiology, highlighting the importance of aligning interventions with distinct genotypic signatures. The findings reinforce the plausibility of omega-3 fatty acids-mediated enhancement of insulin homeostasis and furnish a methodological scaffold for subsequent inquiries that operationalize nutrigenomic stratification within the arena of obesity therapeutics.